Multicenter, open-label, phase 1 study of DSP-7888 Dosing Emulsion (DSP-7888) in patients with advanced malignancies

被引：0
|
作者：
Groves, Morris [2 ]
Hansen, Aaron [3 ]
Harb, Wael [4 ]
Curtis, Kelly [5 ]
Koga-Yamakawa, Erina [6 ]
Origuchi, Makoto [7 ]
Li, Zhonggai [7 ]
Iglesias, Jose [7 ]
Shaib, Walid [8 ]
Spira, Alexander [1 ]
机构：
[1] Virginia Canc Specialists, Fairfax, VA USA
[2] Texas Oncol Austin Midtown, Austin, TX USA
[3] UHN Princess Margaret Canc Ctr, Toronto, ON, Canada
[4] Horizon Oncol Res LLC, Lafayette, IN USA
[5] Syneos Hlth, Phoenix, AZ USA
[6] Sumitomo Dainippon Pharma Co Ltd, Cambridge, MA USA
[7] Boston Biomed Inc, Cambridge, MA USA
[8] Emory Univ, Atlanta, GA 30322 USA
来源：
JOURNAL FOR IMMUNOTHERAPY OF CANCER | 2019年 / 7卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P355
引用
收藏
页数：2
相关论文
共 50 条
  • [31] First-in-human, multicenter, open-label, phase I study of ATOR-1017 (evunzekibart), a 4-1BB antibody, in patients with advanced solid malignancies
    Carneiro, Ana
    Hahn, Amanda
    Ellmark, Peter
    Enell Smith, Karin
    Schultz, Lena
    Ambarkhane, Sumeet
    Yachnin, Jeffrey
    Ullenhag, Gustav J.
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2025, 13 (01)
  • [32] A FIRST-IN-HUMAN, MULTICENTER, PHASE 1/2, OPEN-LABEL STUDY OF XTX101 IN PATIENTS WITH ADVANCED SOLID TUMORS
    Powderly, John
    Norman, Teleen
    Duncan, Meghan
    Huber, Martin
    O'Neil, Jennifer
    Patel, Ekta
    Vandross, Andrae
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2021, 9 : A549 - A549
  • [33] Phase II open-label study of sunitinib in patients with advanced breast cancer
    Denise A. Yardley
    E. Claire Dees
    Stephen D. Myers
    Sherry Li
    Paul Healey
    Zhixiao Wang
    Marla J. Brickman
    Jolanda Paolini
    Kenneth A. Kern
    Dennis L. Citrin
    Breast Cancer Research and Treatment, 2012, 136 : 759 - 767
  • [34] Phase II open-label study of sunitinib in patients with advanced breast cancer
    Yardley, Denise A.
    Dees, E. Claire
    Myers, Stephen D.
    Li, Sherry
    Healey, Paul
    Wang, Zhixiao
    Brickman, Marla J.
    Paolini, Jolanda
    Kern, Kenneth A.
    Citrin, Dennis L.
    BREAST CANCER RESEARCH AND TREATMENT, 2012, 136 (03) : 759 - 767
  • [35] A Phase Ib Open-Label Multicenter Study of AZD4547 in Patients with Advanced Squamous Cell Lung Cancers
    Paik, Paul K.
    Shen, Ronglai
    Berger, Michael F.
    Ferry, David
    Soria, Jean-Charles
    Mathewson, Alastair
    Rooney, Claire
    Smith, Neil R.
    Cullberg, Marie
    Kilgour, Elaine
    Landers, Donal
    Frewer, Paul
    Brooks, Nigel
    Andre, Fabrice
    CLINICAL CANCER RESEARCH, 2017, 23 (18) : 5366 - 5373
  • [36] Phase I, multicenter, open-label, dose-escalation study of sonidegib in Asian patients with advanced solid tumors
    Minami, Hironobu
    Ando, Yuichi
    Ma, Brigette Buig Yue
    Lee, Jih-Hsiang
    Momota, Hiroyuki
    Fujiwara, Yutaka
    Li, Leung
    Fukino, Koichi
    Ito, Koji
    Tajima, Takeshi
    Mori, Asuka
    Lin, Chia-Chi
    CANCER SCIENCE, 2016, 107 (10) : 1477 - 1483
  • [37] An open-label, multicenter, phase I study of ATG-022 in patients with advanced/metastatic solid tumors (CLINCH).
    Bishnoi, Sarwan
    Cao, Dan
    Mendis, Shehara Ramyalini
    Coward, Jim
    Zhao, Jun
    Xie, Hui
    Zheng, Li
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [38] Phase II Multicenter, Open-Label Study of Oral ENMD-2076 for the Treatment of Patients with Advanced Fibrolamellar Carcinoma
    Abou-Alfa, Ghassan K.
    Mayer, Robert
    Venook, Alan P.
    O'Neill, Allison F.
    Beg, Muhammad S.
    LaQuaglia, Michael
    Kingham, Peter T.
    Kobos, Rachel
    Basturk, Olca
    Brennan, Cameron
    Yopp, Adam
    Harding, James J.
    Leong, Stephen
    Crown, John
    Hoti, Emir
    Leonard, Gregory
    Ly, Michele
    Bradley, Mikaela
    Valentino, Emily
    Markowitz, David
    Zukiwski, Alexander
    Ren, Ken
    Gordan, John D.
    ONCOLOGIST, 2020, 25 (12): : E1837 - E1845
  • [39] A Phase 1/2A Open-Label Study of Pralatrexate and Gemcitabine in Patients with Relapsed or Refractory Lympboprolifierative Malignancies
    Horwitz, Steven M.
    Vose, Julie M.
    Advani, Ranjana
    Sankhala, Kamalesh
    Padmanabhan, Swaminathan
    Hamlin, Paul A., Jr.
    Chen, Andy
    Wilroy, Shannon
    Zain, Jasmine M.
    Wright, Danielle
    Weissbrot, Hanna
    Hohenstein, Maribeth
    Cagnoni, Pablo J.
    Saunders, Michael E.
    O'Connor, Owen A.
    BLOOD, 2008, 112 (11) : 557 - 557
  • [40] Evaluation of an alternative ruxolitinib dosing regimen in patients with myelofibrosis: an open-label phase 2 study
    Moshe Talpaz
    Susan Erickson-Viitanen
    Kevin Hou
    Solomon Hamburg
    Maria R. Baer
    Journal of Hematology & Oncology, 11
12345